Ironwood Pharmaceuticals
We are committed to advancing the treatment of GI diseases and redefining the standard of care for GI patients.
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (9 %) | 6 % | (1 %) | 8 % | (21 %) | (23 %) | (4 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 41 % | 56 % | 63 % | 43 % | 29 % | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 27 % | 128 % | 43 % | (226 %) | - | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 23 % | 17 % | 11 % | 26 % | 32 % | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Ironwood Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing innovative medicines for patients with gastrointestinal (GI) diseases. The company primarily serves patients and healthcare providers in the GI therapeutic area, focusing on conditions such as irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Ironwood operates in the highly competitive biopharmaceutical market, where it leverages its scientific expertise and strategic partnerships to bring differentiated products to market.
Ironwood's business model revolves around the research, development, and commercialization of novel therapeutics. The company generates revenue through product sales, licensing agreements, and strategic collaborations. By focusing on delivering effective treatments and generating strong financial returns, Ironwood aims to inspire continued support from both patients and shareholders, thereby enabling further advancements in GI disease therapies.
Keywords: biopharmaceutical, gastrointestinal diseases, innovative medicines, IBS-C, CIC, research, development, commercialization, strategic partnerships, shareholder value.
Tech stack
Investments by Ironwood Pharmaceuticals
Edit